Opexa Therapeutics Inc (NASDAQ:OPXA) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 15, 2016
Zacks Investment Research has upgraded Opexa Therapeutics Inc(NASDAQ:OPXA) to Hold in a statement released on 9/16/2016.
Boasting a price of $3.32, Opexa Therapeutics Inc (NASDAQ:OPXA) traded 3.11% higher on the day. The last stock price is up 2.40% relative to the 200-day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. OPXA has recorded a 50-day average of $4.18 and 200-day average of $3.24. 134,446 shares of the stock were exchanged, up from ann avg. volume of 80,233
See Graphic Below:
Opexa Therapeutics Inc has a one-year low of $1.69 and a 52 week high of $5.10 and has a total market value of $0.0.
About Opexa Therapeutics Inc (NASDAQ:OPXA)
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, and the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.